Insights

Better decisions begin with deeper understanding.

Explore the expertise, insights, and perspectives from OPEN Health that help transform complexity into clarity across today’s healthcare landscape.

Showing 253–261 of 1,050 insights

Close-up of glossy, purple and pink spheres clustered together, reflecting light against a blurred magenta background. The arrangement gives a shiny, abstract, and futuristic appearance.

Thought Leadership

Novel Oncology Therapies Require Innovative Methods in Oncology Modeling

A smiling older man and woman sit together on a white sofa in a bright living room. The woman wears a headscarf, and both appear happy and relaxed as they laugh together.

Thought Leadership

Incorporating the Patient Voice in Publications: How to Identify Representative Patients

A smiling mother holds her laughing baby while a doctor uses a stethoscope to check the baby's chest during a medical examination in a bright room.

Thought Leadership

A Thoughtful Approach to Patient Inclusion in Publications

An older man in a brown shirt smiles while sitting on a sofa, talking to another person. A pink semi-circle design appears on the wall in the background.

Whitepapers

Embracing the Patient Voice Within Publications

Two textured rings, one pink and sparkly and the other fuzzy and purple, intertwine against a gradient background of dark purple and magenta tones.

Thought Leadership

Living Patient Centricity Through Our OPEN Approach

Thought Leadership

Expanding the Role of Medical Affairs: A Focus on Omnichannel Execution, Artificial Intelligence, and Health Equality

Thought Leadership

Coming Soon: Joint Clinical Health Technology Assessments

Celebrating Women in Science at OPEN Health

Thought Leadership

The Evolving Role of RWE to Support Your Medical Strategy

Microscopic image of tissue stained with pink and purple dye, showing layers of cells with dense clusters and some empty spaces, commonly seen in histology slides for medical examination.

Publications

Cost-effectiveness of Nivolumab plus Ipilimumab for the first-line treatment of intermediate/poor-risk advanced and/or metastatic renal cell carcinoma in Switzerland